263 related articles for article (PubMed ID: 12658064)
1. Effects of GP IIb/IIIa receptor inhibitor tirofiban (aggrastat) in ex vivo canine arteriovenous shunt model of stent thrombosis.
Rukshin V; Azarbal B; Finkelstein A; Shah PK; Cercek B; Tsang V; Kaul S
J Cardiovasc Pharmacol; 2003 Apr; 41(4):615-24. PubMed ID: 12658064
[TBL] [Abstract][Full Text] [Related]
2. Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis.
Rukshin V; Shah PK; Cercek B; Finkelstein A; Tsang V; Kaul S
Circulation; 2002 Apr; 105(16):1970-5. PubMed ID: 11997285
[TBL] [Abstract][Full Text] [Related]
3. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis.
Makkar RR; Litvack F; Eigler NL; Nakamura M; Ivey PA; Forrester JS; Shah PK; Jordan RE; Kaul S
Circulation; 1997 Feb; 95(4):1015-21. PubMed ID: 9054765
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic activity of Z4A5, a new platelet glycoprotein IIb/IIIa receptor antagonist evaluated in a rabbit arteriovenous shunt thrombosis model.
Jing BB; Li YX; Zhang H; Ren ST; Wang M; Li YP; Zang WJ; Wang B
Thromb Res; 2011 Nov; 128(5):463-9. PubMed ID: 21924458
[TBL] [Abstract][Full Text] [Related]
5. Intravenous magnesium in experimental stent thrombosis in swine.
Rukshin V; Azarbal B; Shah PK; Tsang VT; Shechter M; Finkelstein A; Cercek B; Kaul S
Arterioscler Thromb Vasc Biol; 2001 Sep; 21(9):1544-9. PubMed ID: 11557686
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons.
Rao AK; Sun L; Hiramatsu Y; Gorman JH; Edmunds LH
Thromb Haemost; 1999 Jul; 82(1):140-4. PubMed ID: 10456468
[TBL] [Abstract][Full Text] [Related]
7. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban.
Umemura K; Kondo K; Ikeda Y; Nakashima M
Thromb Haemost; 1997 Nov; 78(5):1381-4. PubMed ID: 9408023
[TBL] [Abstract][Full Text] [Related]
8. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.
Goto S; Tamura N; Ishida H
J Am Coll Cardiol; 2004 Jul; 44(2):316-23. PubMed ID: 15261925
[TBL] [Abstract][Full Text] [Related]
9. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
10. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen M
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
[TBL] [Abstract][Full Text] [Related]
11. Prolonged inhibition of acute arterial thrombosis by high dosing of a monoclonal anti-platelet glycoprotein IIb/IIIa antibody in a baboon model.
Kotzé HF; Badenhorst PN; Lamprecht S; Meiring M; Van Wyk V; Nuyts K; Stassen JM; Vermylen J; Deckmyn H
Thromb Haemost; 1995 Aug; 74(2):751-7. PubMed ID: 8585017
[TBL] [Abstract][Full Text] [Related]
12. The effect of tirofiban on microvascular thrombosis: crush model.
Yates YJ; Farias CL; Kazmier FR; Puckett CL; Concannon MJ
Plast Reconstr Surg; 2005 Jul; 116(1):205-8. PubMed ID: 15988269
[TBL] [Abstract][Full Text] [Related]
13. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
Zhao XQ; Théroux P; Snapinn SM; Sax FL
Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731
[TBL] [Abstract][Full Text] [Related]
14. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
15. P-selectin antagonism reduces thrombus formation in humans.
Chelliah R; Lucking AJ; Tattersall L; Daga S; Beresford-Cleary NJ; Cortas K; Fox KA; Feuerstein GZ; Connolly TM; Newby DE
J Thromb Haemost; 2009 Nov; 7(11):1915-9. PubMed ID: 19691482
[TBL] [Abstract][Full Text] [Related]
16. The glycoprotein IIb/IIIa platelet receptor blocker tirofiban, but not heparin, counteracts platelet aggregation in unstable angina pectoris.
Mattsson E; Martinsson A; Nyqvist O; Rasmanis G; Sylvén C; Karlberg KE
Am J Cardiol; 1997 Oct; 80(7):938-40. PubMed ID: 9382012
[TBL] [Abstract][Full Text] [Related]
17. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
Talarico GP; Brancati M; Burzotta F; Porto I; Trani C; De Vita M; Todaro D; Giammarinaro M; Leone AM; Niccoli G; Andreotti F; Mazzari MA; Schiavoni G; Crea F
J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):245-51. PubMed ID: 19262211
[TBL] [Abstract][Full Text] [Related]
18. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Dyke CM
Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban.
Koster A; Kukucka M; Bach F; Meyer O; Fischer T; Mertzlufft F; Loebe M; Hetzer R; Kuppe H
Anesthesiology; 2001 Feb; 94(2):245-51. PubMed ID: 11176088
[TBL] [Abstract][Full Text] [Related]
20. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
